Patents Assigned to Genentech
  • Methods and compositions for targeting polyubiquitin
    Patent number: 9081015
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: July 14, 2015
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto
  • COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20150190506
    Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.
    Type: Application
    Filed: December 17, 2014
    Publication date: July 9, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jeanne CHEUNG, Jeong KIM
  • STABILIZING POLYPEPTIDES WHICH HAVE BEEN EXPOSED TO UREA
    Publication number: 20150190514
    Abstract: Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jefferson C. EMERY, Paul J. MCDONALD, Rhona M. O'LEARY
  • TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS
    Publication number: 20150191487
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 9, 2015
    Applicant: Genentech, Inc.
    Inventors: Michael Patrick Dillon, Ronald Charles Hawley, Li Chen, Lichun Feng, Minmin Yang
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20150182537
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: December 3, 2014
    Publication date: July 2, 2015
    Applicant: GENENTECH, INC.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • Anti-hemagglutinin antibodies and methods of use
    Patent number: 9067979
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: June 30, 2015
    Assignee: Genentech, Inc.
    Inventors: Min Xu, Mercedesz Balazs, Ning Chai, Nancy Chiang, Henry Chiu, Zhonghua Lin, Patrick Lupardus, Gerald R. Nakamura, Hyunjoo Park, Lee Swern
  • Compounds and methods of use
    Patent number: 9067928
    Abstract: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: June 30, 2015
    Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Jonathan Bayldon Baell, Chinh Thien Bui, Peter Colman, Danette A. Dudley, Wayne J. Fairbrother, John A. Flygare, Guillaume Laurent Lessene, Chudi Ndubaku, George Nikolakopoulos, Carl Steven Rye, Brad Edmund Sleebs, Brian John Smith, Keith Geoffrey Watson, Steven W. Elmore, Andrew M. Petros, Andrew J. Souers, Peter Czabotar
  • Anti-IL13 antibodies and uses thereof
    Patent number: 9067994
    Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: June 30, 2015
    Assignee: Genentech, Inc.
    Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
  • Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
    Patent number: 9068230
    Abstract: The invention provides methods and kits useful for predicting or assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: June 30, 2015
    Assignee: Genentech, Inc.
    Inventors: David Dornan, Bart Burington
  • Activin receptor-like kinase-1 compositions and methods of use
    Patent number: 9066930
    Abstract: Disclosed herein are methods and compositions for treating disorders associated with angiogenesis or lymphangiogenesis using ALK-1 antagonists.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: June 30, 2015
    Assignee: Genentech, Inc.
    Inventors: Minhong Yan, Gu Zhang
  • SUBSTITUTED PYRAZOLES AND USES THEREOF
    Publication number: 20150175619
    Abstract: The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Applicant: GENENTECH, INC.
    Inventors: Michael Siu, Anthony Estrada, Wen Liu, Joseph P. Lyssikatos, Snahel Patel, Guibai Liang, Kevin Chen
  • TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR
    Publication number: 20150166569
    Abstract: The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: February 13, 2015
    Publication date: June 18, 2015
    Applicant: Genentech, Inc.
    Inventors: Steven Staben, Georgette Castanedo, Christian A.G.N. Montalbetti, Jianwen Feng
  • POLYMORPHS OF 2-(4-(2-(1-ISOPROPYL-3-METHYL-1H-1,2,4-TRIAZOL-5-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPANAMIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
    Publication number: 20150166570
    Abstract: The present invention relates to crystalline polymorphs of (2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (GDC-0032, taselisib), methods of use, and processes of preparing thereof.
    Type: Application
    Filed: December 15, 2014
    Publication date: June 18, 2015
    Applicant: GENENTECH, INC.
    Inventor: Jeffrey Stults
  • ANTI-CD3 ANTIBODIES AND METHODS OF USE
    Publication number: 20150166661
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 18, 2015
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng CHEN, Mark S. DENNIS, Allen J. EBENS, JR., Teemu T. JUNTTILA, Robert F. KELLEY, Mary A. MATHIEU, Liping L. SUN
  • DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT BY DETECTING KRAS MUTATION AND RTK EXPRESSION LEVELS
    Publication number: 20150164895
    Abstract: The present invention relates to prognostic methods for identifying tumors that are not susceptible to B-Raf inhibitor treatment by detecting mutations in a K-ras gene or protein or by detecting overexpression of RTKs and/or their ligands. Kits are also disclosed for carrying out the methods.
    Type: Application
    Filed: May 21, 2014
    Publication date: June 18, 2015
    Applicant: GENENTECH, INC.
    Inventors: Georgia Hatzivassiliou, Shiva Malek
  • ANTI-PRO87299 ANTIBODIES
    Publication number: 20150166631
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.
    Type: Application
    Filed: August 5, 2014
    Publication date: June 18, 2015
    Applicant: GENENTECH, INC.
    Inventors: Hilary Clark, Daniel L. Eaton, Bernd Wranik, Wenjun Ouyang, Lino Gonzalez, Austin L. Gurney
  • Anti-PMEL17 antibodies and immunoconjugates
    Patent number: 9056910
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: June 16, 2015
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY
    Publication number: 20150158846
    Abstract: Heteroaryl pyridone and aza-pyridone amide compounds with electrophilic functionality of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: December 4, 2014
    Publication date: June 11, 2015
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, BinQing Wei, Wendy B. Young
  • PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20150158851
    Abstract: Provided herein are compounds of formula (AA): stereoisomers or a pharmaceutically acceptable salt thereof, wherein A, Ra, p, R5 and R6 are defined herein, compositions including the compounds and methods of manufacturing and using the compounds for the treatment of diseases.
    Type: Application
    Filed: February 10, 2015
    Publication date: June 11, 2015
    Applicant: Genentech, Inc.
    Inventors: Jason Burch, Frederick Brookfield, Richard A. Goldsmith, Kevin Hon Luen Lau, Colin H. MacKinnon, Daniel Fred Ortwine, Zhonghua Pei
  • CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20150158952
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: November 24, 2014
    Publication date: June 11, 2015
    Applicant: GENENTECH, INC.
    Inventors: Weiguang MAO, Jagath Reddy JUNUTULA, Paul POLAKIS